Please login to the form below

Akorn

This page shows the latest Akorn news and features for those working in and with pharma, biotech and healthcare.

Data integrity scuppers Fresenius deal with Akorn

Akorn is furious about the decision, and says it intends to hold Fresenius to its obligations under the merger agreement. ... Akorn can claim a termination fee, which in the original merger agreement was valued at $129m.

Latest news

Fresenius says Akorn investigation could affect takeover

The company says it is conducting an independent investigation - using external experts - into “alleged breaches of FDA data integrity requirements relating to product development at Akorn”. ... Sales for Akorn’s small consumer health business
Fresenius Kabi buys Akorn and Merck's biosimilar businesses

Fresenius is paying $34 per share for Akorn - valuing the company at $4.3bn - and will also assume around $450m in debt held by the US firm. ... Rumours of a deal have been circulating for several weeks, and Akorn confirmed it was in negotiations with
Survival strategy

A recent example of Big Pharma's entry into the generic marketplace was the purchase by Pfizer in December of 22 abbreviated new drug applications for $56m from the Akorn-Strides ... 80. Akorn-Strides/Pfizer. Acquisition of 22 ANDAs in US. Registration.

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

Latest Intelligence

Deal Watch - May 2017

is making two acquisitions worth over $5.5bn. The acquisition of Akorn, a US based company that manufactures “alternate” formulations such as liquids, gels and injectables and markets a range of ... 6, 100. Akorn (US). Fresenius (DE). Company
Pharma deals during September 2014

The contract manufacturing sector is in a state of flux with the acquisition of Patheon last year by DSM and Akorn's acquisition of the ophthalmic manufacturer Excelvision in July this
Deal Watch table for June 2014

45. ECR Pharmaceuticals / Valeant. Company acquisition. Akorn subsidiary with branded generics business.
Deal Watch table for May 2014

VersaPharm / Akorn. Company acquisition. US generic company selling dermatology products with $100m sales.
Pharma deals during May 2014

Merck sold its US ophthalmic business in 2013 for 1.5 x sales to Akorn. ... Akorn acquired Versapharm, a privately-owned US company that develops and markets generic dermatology products.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping: Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much: Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website: You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...